MicroRNA 3607: A Drug Target / Disease Biomarker (G100500805)

Target Name: MicroRNA 3607

NCBI ID: G100500805

MicroRNA 3607

Other Name(s): MIR3607

MicroRNA 3607: A Drug Target / Disease Biomarker

MicroRNA (miRNA) 3607 is a non-coding RNA molecule that plays a critical role in various cellular processes. It is a part of the 3607 family of miRNAs, which are known for their ability to target specific mRNAs for degradation. In recent years, significant research has been conducted on the functions of miRNA 3607 and its potential as a drug target or biomarker.

MiRNA 3607 is a 24.1 kilobase (kb) RNA molecule with 191 nucleotides. It is characterized by a head domain that contains a conserved core sequence of 19 amino acids, followed by a non-coding tail domain that includes a series of novel amino acids. The tail domain of miRNA 3607 is unique, as it contains a unique farnesylated cysteine residue, which is important for its stability and function.

One of the most significant functions of miRNA 3607 is its role in cell signaling pathways. miRNA 3607 is involved in the regulation of various cellular processes, including cell growth, apoptosis, and inflammation. It is well established that miRNA 3607 plays a negative role in the regulation of cell apoptosis, which is the process by which cells die naturally in response to various stimuli.

Studies have shown that miRNA 3607 is highly expressed in various tissues and cells, including brain, pancreas, and heart. It is also shown to be involved in the regulation of various cellular processes, including cell adhesion, migration, and invasion. In addition, miRNA 3607 has been shown to play a role in the regulation of inflammation, which is a critical immune response to harmful substances in the body.

In addition to its role in cellular signaling pathways, miRNA 3607 has also been shown to have potential as a drug target. The unique farnesylated cysteine residue in the tail domain of miRNA 3607 makes it a promising target for small molecule inhibitors. Several studies have shown that miRNA 3607 is responsive to small molecule inhibitors, and that these inhibitors can significantly reduce the levels of miRNA 3607 in various cell types.

Furthermore, miRNA 3607 has also been shown to be a potential biomarker for various diseases, including cancer. Studies have shown that miRNA 3607 levels are significantly altered in various types of cancer, and that these changes can be used as a biomarker for disease diagnosis and prognosis.

In conclusion, miRNA 3607 is a non-coding RNA molecule that plays a critical role in various cellular processes. Its functions include cell signaling pathways, cell apoptosis, inflammation, and biomarker development. The unique farnesylated cysteine residue in the tail domain of miRNA 3607 makes it a promising target for small molecule inhibitors, and its potential as a drug target or biomarker should be further explored.

Protein Name: MicroRNA 3607

The "MicroRNA 3607 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MicroRNA 3607 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets